Evidence map›Paper›PMID 42002979›Full record

ReviewCurrent cancer drug targets2026

The Function of PPARα in Cancer Drug Development: A Promising Target for Cancer Treatment.

Rasiravathanahalli Kaveriyappan Govindarajan, Ragothaman Prathiviraj, Mohammed Qasim Waheeb, Mohammed A Al-Duais, Abdulrahman Asmari, Chellasamy Panneerselvam, Igor Rzhepakovsky, Sergey Povetkin, Hans-Uwe Dahms

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rasiravathanahalli Kaveriyappan GovindarajanDepartment of Biotechnology, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, 641021, India.ORCID 0000-0001-7099-0191
Ragothaman PrathivirajDepartment of Microbiology, Pondicherry University, Puducherry, 605014, India.
Mohammed Qasim WaheebDepartment of Biology, College of Science, Al Muthanna University, Al Muthanna Province, Samawah, 66001, Iraq.
Mohammed A Al-DuaisDepartment of Biochemistry, Faculty of Science, University of Tabuk, Tabuk, 71491, Saudi Arabia.
Abdulrahman AsmariDepartment of Biology, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
Chellasamy PanneerselvamDepartment of Biology, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
Igor RzhepakovskyMedical and Biological Faculty, North Caucasus Federal University, Stavropol, 355000, Russia.
Sergey PovetkinMedical and Biological Faculty, North Caucasus Federal University, Stavropol, 355000, Russia.
Hans-Uwe DahmsDepartment of Biomedical Science and Environmental Biology, KMU, Kaohsiung Medical University, No. 100, Shin- Chuan 1st Road, Kaohsiung 80708, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the leading causes of mortality globally. PPAR modulators may hold great potential for the management of cancer patients. PPAR modulators also activate specific transcriptional pathways, regulate immune responses and inflammation, and influence the proliferation of various cancer cell types. In the last decade, emerging evidence has shown that PPARα, a nuclear hormone receptor, can modulate carcinogenesis via exerting effects on one or several characteristic pathological behaviors of cancer. This review summarizes current knowledge of PPARα function in various aspects of cancer development and the modulators that regulate PPARα. Based on the current knowledge, we have discussed the development of a potential modulator targeting PPARα for cancer treatment.

Indexed as

Antineoplastic AgentsDrug DevelopmentNeoplasmsPPAR alphaAnimalsHumansMolecular Targeted TherapySignal TransductionAntineoplastic AgentsPPAR alphaagonistantagonistcancercancer treatmentmodulatorsPPARPPARα

Identifiers

PMID42002979

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.